What Is Inclusion Body Myositis?
Inclusion body myositis (IBM) is a progressive inflammatory and degenerative muscle disease, the most common acquired muscle disease in adults over 50. It involves both chronic inflammation and abnormal protein accumulation within muscle fibers, making it resistant to standard immunosuppressive therapies.
The disease was first described in the 1960s and takes its name from the abnormal inclusion bodies found inside affected muscle cells. It progresses slowly but relentlessly, and has no FDA-approved disease-modifying treatment as of 2025.
IBM is a convergence of inflammation, protein aggregation, and muscle degeneration that defies the treatments that work for other myopathies.
Sporadic IBM
The most common form. No clear genetic inheritance. Involves immune activation alongside degenerative processes.
Hereditary IBM
A rarer group of genetic conditions with similar pathology but no inflammatory component. Linked to GNE or VCP gene mutations.
Pathology
Endomysial inflammation, rimmed vacuoles, and protein aggregates within muscle fibers, features shared with neurodegenerative disease.
Latest News and Research
How This Page Works
- This tab holds news from the past two months only.
- For the full archive, visit the Research tab.
- Items move to Research once older than three months.
Last compiled: June 29, 2026.
Major Breakthrough: First Drug to Show Significant Results in Autoimmune Myositis Phase 3 Trial
A pharmaceutical company called argenx announced today that their drug efgartigimod (brand name VYVGART Hytrulo) successfully passed a rigorous Phase 3 clinical trial — the gold standard of medical testing — in patients with autoimmune myositis. The trial, called ALKIVIA, enrolled 264 patients across North America, Europe, the Middle East, and Asia-Pacific over a full year.
Think of this as the biggest positive news the myositis community has seen in years. Patients who received the drug improved significantly more than those who got a placebo (dummy injection) — and those improvements started within just 4 weeks and held for the full 12 months of the study, even as steroid doses were being reduced. This is the first time any drug has ever shown this kind of statistically solid result in a large Phase 3 myositis trial.
Who does this affect? The trial focused on two subtypes of autoimmune myositis — IMNM (immune-mediated necrotizing myopathy) and DM (dermatomyositis). IBM (Inclusion Body Myositis) is a different condition, but the underlying research into how pathogenic antibodies drive muscle damage is closely related and may open doors for IBM treatment research. IMNM patients in particular had no approved therapy at all before this — making this result especially significant.
How does the drug work? The immune system produces antibodies — proteins that normally fight infection. In autoimmune myositis, some of these antibodies mistakenly attack the body's own muscle tissue. Efgartigimod works by blocking a protein (called FcRn) that normally recycles these antibodies, causing the harmful antibodies to break down faster and reducing the attack on muscles.
What happens next? argenx will present the full data at an upcoming medical conference and will seek FDA approval. If approved, this would be the first targeted treatment ever available for these myositis subtypes.
Source: argenx official press release, August 17, 2026 — read the full press release
GCOM ABSTRACTS
6th Global Conference on Myositis (GCOM 2026) — Lisbon, Portugal · March 23–26, 2026
The world's premier myositis research forum. IBM-relevant abstracts summarized in plain language for patients and caregivers.
1. Baricitinib Cuts Both Inflammation AND Protein Buildup in IBM — Mouse Study
Researchers at Royal Melbourne Hospital tested baricitinib — a drug already approved for rheumatoid arthritis — in a mouse model that closely replicates IBM. Treating these mice simultaneously halved muscle degeneration, reduced harmful protein buildup (p62+ aggregates), lessened tissue scarring, and extended overall survival.
Why it matters: Most IBM drug candidates target only the immune or only the degenerative side of the disease. This is one of the first to show a single drug can tackle both at once, establishing baricitinib as a strong candidate for human trials.
Authors: Jessica Day, Praneem Vijayakumar, Kael Schoffer et al. — Royal Melbourne Hospital; University of Melbourne; Walter and Eliza Hall Institute
2. A 14-Protein Blood Test That Tells IBM Apart From Polymyositis
A team from Royal Melbourne Hospital and partner institutions developed a blood test using 14 proteins found in IBM patient samples. The test distinguished IBM from polymyositis (a similar but different condition) with 79.5% accuracy — far outperforming existing tools.
Why it matters: IBM is frequently misdiagnosed as polymyositis, leading to years on ineffective treatments. A reliable blood test could dramatically shorten the diagnostic journey for patients.
Authors: Jessica Day, Allan Motyer, Injie Chen, Sam Olechnowicz, Katrina Reardon et al. — Royal Melbourne Hospital; University of Melbourne; St Vincent's; Royal Adelaide Hospital
3. Genome-Wide Study Finds 4 Brand-New Genetic Risk Factors for IBM
The largest genetic study ever conducted specifically on IBM analyzed data from 1,036 IBM cases across Europe. Researchers confirmed the known HLA-DRB1 link and discovered four entirely new genetic risk locations (IKAROS, CD200, RMI2, and ORMDL3), plus a specific gene called IKZF2 that bridges inherited genetic vulnerability with actual muscle cell damage.
Why it matters: These discoveries open completely fresh pathways toward gene-based therapies and personalized medicine for IBM — something researchers have been seeking for decades.
Authors: Nathan Routledge, Alaa Khan, Iwona Skorupinska, and a large international consortium. Funded by the Neuromuscular Study Group (NNSG) and Myositis UK PhD Studentship
4. How IBM's Immune Cells and Muscle Fibers Communicate — And How to Break the Cycle
Using single-nucleus RNA sequencing and spatial transcriptomics (technologies that map gene activity cell by cell inside tissue), researchers found that IBM's damaging immune cells migrate into specific "niches" within inflamed tissue and communicate directly with muscle cells to drive destruction. The study mapped the exact molecular signals fueling this cycle.
Why it matters: Understanding exactly how immune cells and muscle fibers interact gives scientists a precise blueprint for designing drugs that break this self-perpetuating cycle of tissue injury.
Authors: Thorge Dobbertin, Sven Wischnewski, Hannah Kempf, Joelle Olivia Vogelmann, Hans-Werner Rausch, Lucas Schirmer — Medical Faculty Mannheim, Heidelberg University; Mannheim Center for Translational Neuroscience (MCTN)
5. New Blood Test Catches IBM Antibodies That Standard Tests Miss
Researchers at Radboud University developed a new immunofluorescence method for detecting the anti-cN1A antibody — the most IBM-specific blood marker known. Their new assay detected the antibody in 38% of confirmed IBM patient samples, significantly outperforming traditional ELISA test kits which frequently miss it entirely.
Why it matters: Anti-cN1A is the closest thing IBM has to a definitive blood marker, but current tests miss it in many patients. A more sensitive test means fewer missed or delayed diagnoses.
Authors: Gel Prijn, Fleur Brinkman, Isa Verlangen, Filine Swets — Radboud University, Nijmegen, Netherlands
6. MRI and Ultrasound Pinpoint the Exact Cause of Swallowing Difficulty in IBM
This multi-center European study used real-time MRI and quantitative muscle ultrasound to study swallowing difficulties in IBM patients. The imaging demonstrated IBM patients suffer from a unique obstruction linked to a structure called the cricopharyngeal bar — causing measurably delayed food and liquid transit that standard tests cannot isolate.
Why it matters: Knowing the exact physical cause of a patient's choking risk allows clinical teams to target treatment (like cricopharyngeal myotomy surgery) much more accurately and at an earlier stage.
Authors: Rachel Zeng, Anke Rietvelds, Omar Al-Bourini et al. — Multicenter European study (ERN EURO-NMD); partially funded by the Association Française contre les Myopathies and Deutsche Gesellschaft für Muskelkranke
7. IBM Relapses Differently From Other Myositis Types — and That Matters
A large multi-center international study tracking relapses across 239 myositis patients deliberately excluded IBM patients from their relapse prediction model — because the researchers confirmed that relapse patterns seen in other myositis types simply do not apply to IBM's distinct, continuously progressive course.
Why it matters: Unlike dermatomyositis or polymyositis, IBM does not typically "relapse and remit." It progresses steadily. This reinforces why IBM patients need disease-specific monitoring and treatment strategies, not the same approach used for other myositis types.
Authors: Maria Rosa Pelico, Cristina Bochicchio, Claudia Iannone, Silvia Cavalli et al. — Multicenter international retrospective tracker across Italy, UK, India, and Japan
IBM Drug Trial: Ulviprubart Shows 50% Slowing of Disease Progression in Less Advanced Patients
Abcuro presented results from its Phase 2/3 MUSCLE study of ulviprubart (ABC008) at GCOM 2026 — one of the largest IBM clinical trials ever conducted, with 272 patients across multiple countries. While the drug did not hit its primary statistical target in the full patient group, in patients with less advanced IBM at the start of the study, disease progression slowed by 50% compared to placebo.
The drug works by targeting and depleting a specific type of immune cell (KLRG1+ T cells) that destroys muscle tissue in IBM — without broadly suppressing the immune system the way steroids do. It was well tolerated: no patient stopped due to a drug reaction, and fewer patients dropped out of the drug group (2%) than placebo (7%). Abcuro plans to meet with the FDA to discuss next steps. Nearly all study completers are now enrolled in an ongoing long-term extension study.
Source: Abcuro, Inc. — read the full results | view on ClinicalTrials.gov
Peter Frampton on Adapting His Guitar Playing as IBM Progresses
Ahead of his documentary's Tribeca premiere, Frampton told People he has adapted his playing technique as IBM affects his hands. Diagnosed in 2015, he says he continues finding purpose in performing.
Source: People Magazine - read the interview
Documentary Frampton Premieres at Tribeca
The documentary traces Frampton's career from 1970s superstardom through living with IBM, premiering at Tribeca on June 4, 2026.
Source: Live for Films - watch the trailer
VA Secretary Addresses Veterans Pushing for IBM Recognition
Following an investigative documentary, VA Secretary Doug Collins confirmed a National Academies panel is reviewing a possible link between IBM and military service, with findings expected by late 2027.
Source: 11Alive / KGW - read the article
TMA Ask the Expert: IBM Edition Webinar
The Myositis Association hosted a webinar featuring Dr. Jens Schmidt answering IBM patient questions on diagnosis and management.
Source: TMA - watch the webinar
Weight Management Support Sessions
Myositis Support and Understanding offers sessions on weight management for myositis patients, covering both unintended weight loss and weight gain challenges.
Source: MSU - view event details
New IBM-Health Index Could Shape Future Drug Trials
University of Rochester researchers developed the IBM-Health Index, a patient-reported outcome measure capturing mobility, hand function, swallowing, fatigue, pain, and emotional wellbeing for FDA drug-labeling trials.
Source: Journal of Clinical Neuromuscular Disease - view the study (may require subscription)
Wearable Sensors Tested for Arm and Hand Function Tracking
Researchers are studying wrist-worn sensors that track real-world arm and hand movement in IBM patients between clinic visits.
Source: Neurology AAN - view the study (may require subscription)
New Data on Cricopharyngeal Myotomy Symptom Recurrence
New research examines how often swallowing symptoms return after cricopharyngeal myotomy, helping doctors counsel IBM patients on long-term expectations.
Source: Neurology AAN - view the study (may require subscription)
Symptoms and Progression
IBM follows a characteristic pattern of muscle weakness, often asymmetric, targeting specific muscle groups with notable predictability.
Early Symptoms
- Difficulty rising from a chair
- Frequent tripping or falls
- Weakness climbing stairs
- Difficulty gripping objects
- Weakness in finger flexors
- Mild wrist drop
Later Symptoms
- Difficulty swallowing, affects 40-80%
- Loss of ability to walk independently
- Forearm and thigh muscle wasting
- Foot drop requiring AFO bracing
- Aspiration risk from dysphagia
- Respiratory muscle involvement (rare)
The Classic IBM Pattern
- Quadriceps weakness leads to buckling knees and fall risk early on
- Deep finger flexor weakness impairs grip and fine motor tasks, often asymmetrically
- Forearm muscle wasting is a hallmark clinical sign
- Dysphagia can become the most limiting symptom and carries aspiration pneumonia risk
- Proximal leg and distal arm weakness coexist, a distinctive combination
IBM does not typically affect the heart, but 15-20% of patients may have some cardiac abnormality. Cognitive function is generally preserved.
Progression is highly variable. Most patients need a walking aid within 10-15 years. Aspiration pneumonia is a leading cause of mortality from secondary complications.
Diagnosis
IBM is notoriously difficult to diagnose. A diagnostic delay of five to seven years is common due to slow progression and symptom overlap with other conditions.
Blood Tests
CK is elevated in most patients, often mildly. Anti-cN1A antibodies found in 30-70% of cases.
Electromyography
Shows a mixed myopathic and neuropathic pattern, a helpful diagnostic clue.
Muscle Biopsy
The gold standard. Findings include inflammation, rimmed vacuoles, and protein inclusions.
MRI
Shows fatty replacement patterns, particularly in quadriceps and forearm flexors.
A negative biopsy does not rule out IBM. Sampling error is common.
Diagnostic criteria classify patients into clinically defined, probable, or possible IBM based on clinical and pathological features.
Treatment Approaches
There is no FDA-approved disease-modifying treatment for IBM. Steroids and immunosuppressants typically provide no sustained benefit and may worsen muscle wasting.
Why Immunosuppression Doesn't Work
- IBM has a degenerative component independent of inflammation
- Protein aggregates are not cleared by anti-inflammatory drugs
- Long-term steroids can cause steroid myopathy
- IVIG, methotrexate, and other trials have failed to show meaningful benefit
Management focuses on symptomatic and supportive care through a multidisciplinary team of neurologists, physiatrists, therapists, and dietitians.
Physical and Occupational Therapy
- Resistance and aerobic exercise
- Fall prevention training
- Adaptive equipment
- AFOs for foot drop
- Knee bracing
- Home modification assessments
Managing Dysphagia
- Modified texture diets
- Thickened liquids as needed
- Swallowing therapy with SLP
- Cricopharyngeal myotomy
- Dilation procedures
- PEG tube when severe
Exercise remains one of the most evidence-supported interventions, slowing functional decline without worsening inflammation.
Nutrition in IBM
Adequate protein, micronutrient support, dysphagia management, and healthy weight all affect muscle health, fall risk, and disease trajectory.
Protein
1.2-1.6 g/kg body weight daily. Leucine-rich sources are particularly anabolic.
Vitamin D
Deficiency is common and linked to muscle weakness and fall risk.
Omega-3
Modest anti-inflammatory effects. EPA and DHA at 2-4 g/day commonly recommended.
Antioxidants
Vitamins C, E, and polyphenols may help mitigate oxidative cellular damage.
Creatine
3-5 g/day has shown modest benefit preserving muscle strength.
B Vitamins
B12 deficiency is common in older adults and can worsen weakness independently of IBM.
Nutrition and Dysphagia
- Modified texture diets must still provide adequate calories and protein
- Thickened liquids reduce aspiration risk but may reduce fluid intake
- Small frequent meals reduce swallowing fatigue
- Upright positioning 45-90 minutes post-meal reduces aspiration risk
- Consider oral nutritional supplements if intake is insufficient
Recommended Foods
- Eggs, Greek yogurt, cottage cheese
- Fatty fish
- Avocado, nut butters
- Cooked vegetables, soups
- Protein smoothies
- Soft fruits
Foods to Approach with Caution
- Dry crumbly foods
- Thin liquids if dysphagia present
- Stringy meats and raw vegetables
- Sticky foods
- Large meal portions
- Alcohol
Living with IBM
Proactive planning, modifying the home, adopting assistive devices, and building a support network preserves independence and quality of life.
Home Modifications
Grab bars, ramps, raised toilet seats, and stair lifts. Free AOTA home safety checklist
Mobility Aids
Cane to walker to rollator to wheelchair progression is common. Shop byACRE rollators
Adaptive Devices
Jar openers, utensil handles, key turners, and touchscreen tech compensate for grip weakness. See products below
Mental Health
Depression and anxiety are common in IBM. Find a TMA support group
Staying ahead of the disease preserves autonomy longer than reactive coping.
Water-based therapy is particularly beneficial as buoyancy reduces fall risk while enabling movement. See the Water Exercises tab for a full program. Driving safety should be regularly reassessed as weakness progresses.
Click any card to view on Amazon.
As an Amazon Associate, thedisABLEDcompany may earn from qualifying purchases at no extra cost to you.
MagZip Magnetic Zipper by Ankhgear
A magnetic zipper replacement for one-handed use. The two halves snap together magnetically instead of requiring a slider. 27 inch, black, Amazon's Choice, 4.4 stars, $8.99.
Shop on AmazonAdjustable Clip and Pull Dressing Aid by Tovyzalg
A dressing stick that clips onto pants or skirts so you can pull them up one-handed. Adjustable 26 to 41 inches. 2-pack with travel pouch, $9.97.
Shop on AmazonExercise and Physical Activity
The programs below are drawn from Kourage Health, a medically supervised exercise organization experienced with IBM patients, and Dr. Helene Alexanderson, PhD, PT, Associate Professor at Karolinska University Hospital in Stockholm. Always consult your physician and physical therapist before starting a new program.
In IBM, exercise is not optional, it is medicine. The goal is to keep moving consistently in ways your body can sustain.
Flexibility and Mobility
Source: Kourage Health
Overhead Reach with Side Stretch
Raise one arm overhead, lean gently to the opposite side.2x 15-20 sec each sideWatch demo
Wrist Flexor Stretch
Extend arm forward, palm up. Gently bend wrist downward with the other hand.20-40 sec each wristWatch demo
Bicep Wall Stretch
Palm flat on wall at shoulder height, arm straight. Turn body away gently.20-40 sec each armWatch demo
Seated Spinal Twist
Sit tall, rotate torso slowly to one side, hold, return.1-2x 20-40 sec each sideWatch demo (Mayo Clinic)
Chair Hamstring Stretch
Extend one leg, heel on floor, toe up. Hinge gently forward from hips.20-40 sec each legWatch demo
Seated Piriformis Stretch
Cross one ankle over opposite knee, lean gently forward.20-40 sec each legWatch demo
Butterfly Stretch in Chair
Soles of feet together, knees fall gently outward.Hold 20-40 secWatch demo
Towel Calf Stretch
Loop a towel around the ball of one foot, gently pull toes toward you.20-40 sec each legWatch demo
Toe Pulls
Pull toes up toward shin, use a towel if needed.15-30 sec each footWatch demo
Strength and Stability
Source: Kourage Health
Seated Hip Flexion
Lift one knee toward chest, hold, lower with control.2x 6-8 repsWatch demo
Wall Ball Slides with Support
Stability ball or towel under forearms against wall, slide arms up and down.2x 3-8 repsWatch similar demo
Knee Extensions
Seated, slowly straighten one knee, hold briefly, lower slowly.1-2x 4-6 reps each legWatch demo
Seated Towel Rows
Loop towel around a post, pull both ends toward torso, squeeze shoulder blades.2-3x 8-12 repsWatch demo
Quad Sets
Tighten the quadriceps, hold briefly, release. Can be done seated.1-2x 4-8 reps each legWatch demo
Side-Lying Clamshells
Lie on side, knees bent, lift top knee while feet stay together.1-2x 4-6 reps each sideWatch demo
Seated Side Bends
Reach one hand toward floor along outside of chair, return with control.1-2x 4-6 reps each sideWatch demo
Wall Lean Pelvic Tilts
Back against wall, flatten lower back by tilting pelvis, hold, release.1-2x 5-8 repsWatch demo
Balance and Coordination
Source: Kourage Health
Wall Angels
Back against wall, arms out, elbows at 90 degrees, slide arms overhead.2x 4-6 repsWatch demo
Chair Toe Taps
Alternate tapping each toe to the floor in a marching rhythm.1-2x 20-30 secWatch demo
PNF Diagonal Arm Patterns
Slow diagonal arm sweep across body and overhead.2x 5-8 reps each armSpecialized PT technique, ask in person
Core and Functional Movement
Source: Kourage Health
Chair Cat-Cow
Inhale, arch back gently. Exhale, round back and tuck chin.3-5 roundsWatch demo
Seated Spinal Rotations
Cross arms, rotate torso left and right with smooth movement.2-3x 8-10 reps each directionWatch demo
Seated Lumbar Flexion
Hands on thighs, slowly hinge forward, return upright with control.2x 8-10 repsWatch demo
Dr. Alexanderson's Aerobic Program
Source: Helene Alexanderson, Karolinska. Evaluated in Johnson et al., J Clin Neuromusc Dis 2007 and 2009.
Stationary Cycling
Moderate intensity, comfortably breathless but able to talk.30 min, 3x per week, 12 weeks
Sit-to-Stand Practice
Rise from a chair using minimal hand support, lower with control.1-2x 4-8 reps, multiple times dailyWatch demo
Walking at Your Own Pace
Use appropriate mobility aid. Aim to raise heart rate as tolerated.20 min, 3x per week
Exercise Safety Guidelines
- Get physician clearance before starting, especially in a flare or recently diagnosed
- Work with a physical therapist experienced in neuromuscular disease
- Stop if you experience unusual pain or significantly increased weakness
- Soreness lasting more than 24-48 hours may mean intensity is too high
- Consistency matters more than intensity
- Rest days are essential, recovery is slower in IBM
No stage of IBM is too late to benefit from physical activity. Water-based exercise is covered in the Water Exercises tab.
Water Exercises
Water-based exercise is one of the most recommended forms of activity for IBM patients. Water buoyancy supports body weight and dramatically reduces fall risk while still allowing meaningful, full-range movement. Warm water also eases muscle stiffness and joint discomfort, making it easier to move through exercises that might be painful or difficult on land.
Water takes the weight off so the muscles can do the work, without the fear of falling.
Warm-Water Walking
Walk forward, backward, and sideways in chest- or waist-deep warm water. Water resistance builds strength while buoyancy protects joints.10-20 min, as toleratedWatch demo
Pool Noodle Leg Lifts
Holding the pool edge or a noodle for support, lift one leg forward, sideways, and backward through the water.1-2x 8-10 reps each directionWatch demo
Water Arm Circles
Standing in chest-deep water, extend arms out to sides and make slow circles, using water resistance to build shoulder strength.2x 10-15 sec each directionWatch demo
Supported Sit-to-Stand in Pool
Using a pool bench or step, practice sitting and standing with water buoyancy reducing the load on weakened legs.1-2x 6-10 repsWatch demo
Why Water Works for IBM
Benefits of Aquatic Therapy
- Buoyancy reduces effective body weight by up to 90% in chest-deep water, dramatically lowering fall risk
- Water resistance provides gentle, even strengthening in every direction without needing weights
- Warm water (typically 83-90F) eases muscle stiffness and reduces joint pain during movement
- Hydrostatic pressure can help reduce swelling and improve circulation
- Many patients can perform movements in water that are too difficult or unsafe on land
Pool Safety Tips
Before You Go
- Choose a warm-water pool (83-90F) if possible, therapy pools and YMCA programs often have these
- Get physician clearance, especially if you have swallowing difficulty or breathing concerns
- Bring a friend or let a lifeguard know you may need extra support
- Wear secure, supportive water shoes to prevent slipping
While in the Water
- Stay in shallower water until you are confident with your balance
- Use pool noodles, kickboards, or the pool edge for extra support
- Move slowly and avoid sudden direction changes
- Exit the pool carefully, use steps with railings rather than ladders when possible
Research and Clinical Trials
IBM research is accelerating, with new avenues targeting protein aggregation, autophagy dysfunction, and mitochondrial impairment.
Current Research Directions
- Rapamycin/mTOR inhibition: enhances autophagy to clear protein aggregates
- Arimoclomol: a heat shock protein co-inducer, Phase 3 completed with mixed results
- Anti-KLRG1 therapies: target effector memory T-cells resistant to standard immunosuppression
- Exercise interventions: continue producing positive functional outcomes
- Gene therapy and AAV vectors: early-stage investigations
- Biomarker development: anti-cN1A antibodies, neurofilament light chain, muscle MRI scoring
The Myositis Association, Cure IBM, and the IBM Research Collaborative drive patient advocacy and fund research. ClinicalTrials.gov is the definitive resource for finding open studies.
The Myositis Association
myositis.org - advocacy, support groups, and research funding.
Cure IBM
cureibm.org - patient-driven IBM research funding and registry.
ClinicalTrials.gov
clinicaltrials.gov - search for enrolling trials worldwide.